Edesa Biotech (EDSA) Assets Average (2014 - 2026)
Edesa Biotech (EDSA) posted Assets Average of $14.1 million for Q4 2025, little changed sequentially from $14.2 million in Q3 2025, and up 253.98% YoY from $4.0 million in Q4 2024.
Edesa Biotech (EDSA) Assets Average (2014 - 2026) Analysis & Trends
Edesa Biotech has reported Assets Average for 12 years, with the latest figure at $14.1 million in Q4 2025.
- Quarterly Assets Average rose 253.98% year-over-year to $14.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.1 million (up 253.98% YoY) and the FY2025 annual result came in at $8.7 million, up 36.52% from the prior year.
- Assets Average held at $14.1 million in Q4 2025 per EDSA's latest filing, from $14.2 million in the prior quarter.
- Over five years, Assets Average peaked at $20.4 million in Q2 2021 and troughed at $4.0 million in Q4 2024.
- A 5-year average of $12.1 million and a median of $12.5 million in 2021 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2025: Assets Average tumbled 52.29% in 2024, then surged 253.98% in 2025.
- Over 5 years, Assets Average stood at $13.5 million in 2021, then retreated by 13.66% to $11.6 million in 2022, then declined by 28.08% to $8.4 million in 2023, then sank by 52.29% to $4.0 million in 2024, then soared by 253.98% to $14.1 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $14.1 million, $14.2 million, and $15.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.69 Bn | 130.84 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.29 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.79 Bn | 59.60 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.44 Bn | 54.31 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.92 Bn | 27.61 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.10 Bn | 9.71 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.33 Bn | 26.17 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 19.82 Bn |
| 10 | Edesa Biotech | 43.06 Mn | 43.06 Mn | - | 13.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.72 Mn |
| Dec 31, 2025 | 14.12 Mn |
| Sep 30, 2025 | 14.17 Mn |
| Jun 30, 2025 | 15.63 Mn |
| Mar 31, 2025 | 10.31 Mn |
| Dec 31, 2024 | 3.99 Mn |
| Sep 30, 2024 | 4.52 Mn |
| Jun 30, 2024 | 5.85 Mn |
| Mar 31, 2024 | 7.15 Mn |
| Dec 31, 2023 | 8.36 Mn |
| Sep 30, 2023 | 9.15 Mn |
| Jun 30, 2023 | 10.05 Mn |
| Mar 31, 2023 | 11.17 Mn |
| Dec 31, 2022 | 11.63 Mn |
| Sep 30, 2022 | 14.56 Mn |
| Jun 30, 2022 | 18.97 Mn |
| Mar 31, 2022 | 16.38 Mn |
| Dec 31, 2021 | 13.46 Mn |
| Sep 30, 2021 | 15.73 Mn |
| Jun 30, 2021 | 20.44 Mn |